These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 28330604)
41. Antibody drug conjugates. Bakhtiar R Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710 [TBL] [Abstract][Full Text] [Related]
42. Ethynylphosphonamidates for the Rapid and Cysteine-Selective Generation of Efficacious Antibody-Drug Conjugates. Kasper MA; Stengl A; Ochtrop P; Gerlach M; Stoschek T; Schumacher D; Helma J; Penkert M; Krause E; Leonhardt H; Hackenberger CPR Angew Chem Int Ed Engl; 2019 Aug; 58(34):11631-11636. PubMed ID: 31250955 [TBL] [Abstract][Full Text] [Related]
43. A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates. Xu Y; Jin S; Zhao W; Liu W; Ding D; Zhou J; Chen S Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29088062 [TBL] [Abstract][Full Text] [Related]
44. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Shochat D; Mountain A Bioconjug Chem; 2005; 16(2):354-60. PubMed ID: 15769089 [TBL] [Abstract][Full Text] [Related]
45. Contribution of linker stability to the activities of anticancer immunoconjugates. Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937 [TBL] [Abstract][Full Text] [Related]
46. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875 [TBL] [Abstract][Full Text] [Related]
47. Generation of DOTA-conjugated antibody fragments for radioimmunoimaging. Smith-Jones PM; Solit DB Methods Enzymol; 2004; 386():262-75. PubMed ID: 15120256 [No Abstract] [Full Text] [Related]
48. Magnetic polycarbonate microspheres for tumor-targeted delivery of tumor necrosis factor. Hu B; Du HJ; Yan GP; Zhuo RX; Wu Y; Fan CL Drug Deliv; 2014 May; 21(3):204-12. PubMed ID: 24117028 [TBL] [Abstract][Full Text] [Related]
49. Improving the serum stability of site-specific antibody conjugates with sulfone linkers. Patterson JT; Asano S; Li X; Rader C; Barbas CF Bioconjug Chem; 2014 Aug; 25(8):1402-7. PubMed ID: 25099687 [TBL] [Abstract][Full Text] [Related]
50. Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends. Huang RY; Chen G Drug Discov Today; 2016 May; 21(5):850-5. PubMed ID: 27080148 [TBL] [Abstract][Full Text] [Related]
51. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715 [TBL] [Abstract][Full Text] [Related]
52. Biotransformation and stability of antibody-drug conjugates: payload metabolism and linker cleavage delineation. Rangan VS; Myler H; Kozhich A; Wang J; Randazzo R; Deshpande S Bioanalysis; 2015; 7(11):1319-23. PubMed ID: 26110704 [No Abstract] [Full Text] [Related]
53. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Xu K; Liu L; Saad OM; Baudys J; Williams L; Leipold D; Shen B; Raab H; Junutula JR; Kim A; Kaur S Anal Biochem; 2011 May; 412(1):56-66. PubMed ID: 21216214 [TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. Burke PJ; Senter PD; Meyer DW; Miyamoto JB; Anderson M; Toki BE; Manikumar G; Wani MC; Kroll DJ; Jeffrey SC Bioconjug Chem; 2009 Jun; 20(6):1242-50. PubMed ID: 19469529 [TBL] [Abstract][Full Text] [Related]
55. Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates. Sukumaran S; Gadkar K; Zhang C; Bhakta S; Liu L; Xu K; Raab H; Yu SF; Mai E; Fourie-O'Donohue A; Kozak KR; Ramanujan S; Junutula JR; Lin K Pharm Res; 2015 Jun; 32(6):1884-93. PubMed ID: 25446772 [TBL] [Abstract][Full Text] [Related]
56. Linker technologies for antibody-drug conjugates. Nolting B Methods Mol Biol; 2013; 1045():71-100. PubMed ID: 23913142 [TBL] [Abstract][Full Text] [Related]
57. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454 [TBL] [Abstract][Full Text] [Related]
58. Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates. DeVay RM; Delaria K; Zhu G; Holz C; Foletti D; Sutton J; Bolton G; Dushin R; Bee C; Pons J; Rajpal A; Liang H; Shelton D; Liu SH; Strop P Bioconjug Chem; 2017 Apr; 28(4):1102-1114. PubMed ID: 28151644 [TBL] [Abstract][Full Text] [Related]
59. Multi-step high-throughput conjugation platform for the development of antibody-drug conjugates. Andris S; Wendeler M; Wang X; Hubbuch J J Biotechnol; 2018 Jul; 278():48-55. PubMed ID: 29733878 [TBL] [Abstract][Full Text] [Related]
60. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]